Brief: Brainstorm Cell Therapeutics Submits Type A Meeting Request To U.S. Food And Drug Administration
12/12/2022 15:17
Dec 12 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS SUBMITS TYPE A MEETING
REQUEST TO
U.S. FOOD AND DRUG ADMINISTRATION
* BRAINSTORM CELL THERAPEUTICS INC - TYPE A MEETING IS
EXPECTED TO
OCCUR WITHIN 30 DAYS OF FDA'S RECEIPT OF MEETING REQUEST
Source text for Eikon: ID:nPn7hrSBxa
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview